GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Deferred Tax

EV Biologics (EV Biologics) Deferred Tax : $-0.10 Mil (TTM As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

EV Biologics's change in deferred tax for the three months ended in Dec. 2017 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2017 was $-0.10 Mil.


EV Biologics Deferred Tax Historical Data

The historical data trend for EV Biologics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Deferred Tax Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Deferred Tax
-0.13 -0.08 -0.33 0.09 0.23

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 -0.10 0.01 - -

EV Biologics Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics Deferred Tax Related Terms

Thank you for viewing the detailed overview of EV Biologics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023